rosiglitazone hydrochloride

rosiglitazone hydrochloride is a drug used to treat type 2 diabetes TZD and it is taken through mouth. It can enhance sensitivity to insulin, Gene transcription regulates insulin response, Control blood sugar production, transport and use, Correct sugar and lipid metabolic abnormalities, reduce fasting and postprandial blood sugar, Improve high glucose poison and can provide the patients with long term blood sugar control.

It has completed pilot and its Process is very stable. Its Post-processing is convenient and has High purity and yield. Its end products meet FDA purity standards.

rosiglitazone hydrochloride was on the market in June 1999 in the united States. It was approved to treat type 2 diabetes. In the weeks after the listing 1, rosiglitazone, into the house of the nation's 20000 and received a warm welcome to the medical profession and patients. In 2000 the first two months, the United States for more than 50 doctors out patients with more than 150 prescription. In 2002, rosiglitazone has been used in more than 400 patients with diabetes, global sales of $1.482 billion, ranking second beyond global sales people, become a global sales of insulin in the oral glucose-lowering products

In 2003, rosiglitazone global sales of $1.706 billion, to remain the global diabetes drug all species and their dosage form ranked first in sales name. In 2004, rosiglitazone global sales of $2.489 billion, global sales to remain in the first. Analysts predicts 2005, rosiglitazone sales income of $3 billion.

http://www.lookchem.com/Rosiglitazone-hydrochloride/http://www.lookchem.com/Rosiglitazone-hydrochloride/